RxDoctor Payments DataLook up a doctor →

Fareed Sheikh, DO

Cardiovascular Disease · Henderson, NVNPI 1871564039

Payments from drug & device makers

$56,279in general payments, 2019–2025

Across 713 payments — averaging $78.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$21K
  • Amarin Pharma, Inc.$18K
  • Cvrx, Inc.$3K
  • Novartis$2K
  • Amgen$1K
  • Merck$1K
  • plus $10K from 38 others

What the payments were for

  • Consulting fees$6,07511%
  • Speaking & faculty fees$16,04029%
  • Travel & lodging$1,5513%
  • Food & beverage$32,54158%
  • Education$720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,279 in reported general payments places this provider in the 90th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$705,715
Medicare patients
2,613
Services billed
10,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$351,309
OpsumitMacitentan24$303,829
EntrestoSacubitril/Valsartan196$285,670
XareltoRivaroxaban131$169,520
FarxigaDapagliflozin Propanediol82$100,005
Repatha SureclickEvolocumab86$78,307
OzempicSemaglutide71$71,710
VerquvoVericiguat54$69,666
MounjaroTirzepatide50$53,985
MultaqDronedarone Hcl33$50,991
VascepaIcosapent Ethyl41$33,447
JardianceEmpagliflozin19$30,816
BrilintaTicagrelor18$22,685
NexletolBempedoic Acid24$22,558
Repatha PushtronexEvolocumab11$14,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$145$351,309275 claims
Actelion Pharmaceuticals US, Inc.Opsumit$822$303,82924 claims
NovartisEntresto$1,994$285,670196 claims
Johnson & JohnsonXarelto$846$169,520131 claims
AstraZenecaFarxiga, Brilinta$250$122,690100 claims
Novo NordiskOzempic$91$71,71071 claims
MerckVerquvo$1,020$69,66654 claims
Sanofi-aventis U.S. LLCMultaq$197$50,99133 claims
Boehringer IngelheimJardiance$101$30,81619 claims
Esperion Therapeutics, Inc.Nexletol$46$22,55824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →